The Joe Rogan ExperienceJoe Rogan Experience #1671 - Bret Weinstein & Dr. Pierre Kory
CHAPTERS
- 0:00 – 1:23
Emergency episode setup: who Dr. Pierre Kory is and why this conversation is urgent
Joe frames the episode as an "emergency podcast" prompted by escalating censorship and the need to discuss COVID treatment debates quickly. Dr. Pierre Kory introduces himself, his ICU/pulmonary background, and the FLCCC’s role in developing COVID protocols—especially outpatient approaches centered on ivermectin.
- •Joe explains the urgency and why the episode was moved up
- •Dr. Kory’s credentials: ICU and pulmonary specialist
- •FLCCC formed early to develop COVID treatment protocols
- •Shift from inpatient protocols to outpatient focus
- •Claimed expertise around ivermectin use in COVID
- 1:23 – 3:06
Bret Weinstein’s COVID analysis background and how ivermectin entered the picture
Bret describes how he and Heather Heying built the DarkHorse COVID coverage by reading papers live and updating conclusions as evidence changed. He explains how early signals around ivermectin surfaced during that ongoing review process.
- •DarkHorse began systematic evidence review early in the pandemic
- •Evolutionary biology as a toolkit for epidemiology and immunity topics
- •Use of preprints and fast-moving literature to build models in real time
- •Early mention of ivermectin as a potential therapeutic signal
- •Transition from general COVID understanding to therapeutics scrutiny
- 3:06 – 4:59
Early ivermectin signal: lab evidence and “bench to bedside” urgency
Dr. Kory recounts the initial in-vitro ivermectin study (cell culture/monkey kidney cells) showing dramatic reduction of viral material, which some regions translated into clinical use during an emergency. The group emphasizes ivermectin’s long safety record and low cost as key context.
- •First major signal came from a cell-culture (not human) study
- •Some clinicians adopted use due to pandemic urgency
- •Ivermectin characterized as widely used and generally safe
- •Discussion of the normal difficulty of moving from lab to clinical efficacy
- •Cost/patent status begins to loom as an underlying theme
- 4:59 – 8:05
YouTube strikes and the problem of defining “deceptive medical information”
Joe and Bret detail YouTube’s strikes, removed videos, and confusing enforcement, including labeling content as "spam" or "deceptive medical information." They argue platform rules defer to agencies (CDC/FDA/WHO) even when those agencies conflict or lag evidence.
- •YouTube strikes/warnings applied inconsistently across channels
- •Removed content includes episodes with Rogan and with medical guests
- •Policy relies on CDC/FDA/WHO guidance as the boundary of acceptable speech
- •Bret argues the rules are unclear until punishment arrives
- •Central question: who decides what is misinformation during a fast-evolving crisis?
- 8:05 – 18:38
Agency contradictions: remdesivir, vaccines, and airborne/aerosol transmission
The guests cite examples where major health bodies disagree, focusing on remdesivir adoption in the U.S. vs WHO skepticism and disputes over airborne transmission. They argue these mismatches illustrate why open scientific debate is necessary and why agency alignment cannot be treated as unquestionable truth.
- •Remdesivir: WHO discourages; U.S. hospitals widely use despite modest outcomes
- •Cost and patent incentives contrasted with generic ivermectin
- •Airborne/aerosol transmission debate and delayed institutional acknowledgment
- •Actionable implications: ventilation, time-in-room, and masking limits
- •Suggestion that non-scientific factors influence official guidance
- 18:38 – 29:28
Lab-leak narrative reversal and the broader theme: misinformation vs disinformation
Joe and Bret discuss how lab-leak discussion was once censored but later became mainstream, using it as a cautionary example of premature “consensus.” Dr. Kory frames this as disinformation tactics used to suppress inconvenient science, drawing parallels to ivermectin.
- •Lab-leak hypothesis shifted from taboo to plausible without a single decisive new fact
- •Media and institutional pressure shaped what could be said publicly
- •Fauci/Andersen emails referenced as evidence of behind-the-scenes doubts
- •Dr. Kory distinguishes misinformation (alleged) from disinformation (strategic suppression)
- •Argument: the lab-leak episode should teach skepticism toward authority-enforced narratives
- 29:28 – 40:48
How “real” scientific consensus forms vs. top-down consensus enforced by platforms
Bret contrasts organic scientific consensus (built through challenge and correction) with “official consensus” declared during an emerging pandemic. The group argues platforms and agencies are suppressing the necessary adversarial process that normally refines truth.
- •Example of real consensus: plate tectonics emerged through prolonged dispute and evidence
- •Pandemic-era “consensus” is portrayed as top-down and prematurely fixed
- •Value of showing work, updating errors, and inviting pushback
- •Independence vs institutional incentives: why 'heretics' may notice problems sooner
- •YouTube compared to a “department chair” pressuring compliance
- 40:48 – 57:48
Ivermectin evidence basics: RCTs, meta-analyses, and what critics are (and aren’t) saying
Bret and Dr. Kory outline the evidence landscape: many trials, noisy signals, and meta-analyses intended to pool results and reduce protocol-specific error. They argue critics improperly demand only large single RCTs while dismissing the cumulative evidence and the precautionary principle for a safe drug.
- •Many randomized trials exist; meta-analyses pool them to identify signal
- •Critics argue for large trials; guests argue this sets an impractical bar
- •Safety history emphasized as decisive in a pandemic risk-benefit calculation
- •Meta-analysis described as the top of the evidence pyramid (vs single RCT)
- •Claimed mortality reduction and strong effect when treated early
- 57:48 – 1:11:21
Prophylaxis claim: prevention rates, dosing nuances, and the “end the pandemic” argument
The discussion spotlights ivermectin as prevention (prophylaxis), citing a meta-analysis line suggesting large reduction in infection and specific studies in healthcare workers with dramatic contrasts vs controls. They discuss dosing frequency, co-interventions (e.g., carrageenan spray), and how prevention could theoretically drive extinction.
- •Distinction: prophylaxis (prevention) vs treatment
- •Meta-analysis cites large reduction in infection risk; “low certainty” defined technically
- •Healthcare-worker study: near-zero infections in treated vs high infection in controls
- •Protocol details: weekly vs monthly dosing and taking with fat for absorption
- •Claim: sufficient prophylaxis compliance could push effective R below 1
- 1:11:21 – 1:22:23
Follow-the-money hypothesis: patents, EUAs, Merck’s reversal, and the $3B antiviral push
Bret and Dr. Kory speculate that profit incentives and regulatory structures explain the hostility to cheap repurposed drugs. They highlight Merck’s unusual stance against its own product, the role of Emergency Use Authorizations (EUAs), and public funding aimed at new patented antivirals despite existing candidates.
- •Merck criticized ivermectin’s use despite its own history distributing it widely
- •New patented drug pipeline (e.g., molnupiravir) contrasted with generic ivermectin
- •NYT/Carl Zimmer article used to frame hospital vs outpatient antiviral strategy
- •Fauci’s announced multibillion-dollar initiative to develop new antivirals
- •EUA argument: authorizations hinge on lack of existing safe/effective treatments
- 1:22:23 – 2:06:09
Real-world rollouts: Mexico’s test-and-treat, Argentina/La Pampa, India, and variant claims
Dr. Kory cites population-level “natural experiments” where ivermectin adoption allegedly correlates with rapid declines in hospitalizations and deaths. The conversation argues these large-scale signals are being ignored by major media and agencies, and discusses why effects should plausibly extend across variants due to multiple mechanisms.
- •Mexico IMSS test-and-treat program: claimed rapid drops in hospitalizations/deaths
- •Argentina (La Pampa) and other regions report reductions in severe outcomes
- •India state-by-state contrasts presented as a natural experiment
- •Discussion of variants (Delta, Beta, P.1, UK) and why ivermectin should still work
- •Claim of muted media response and institutional resistance despite scale
- 2:06:09 – 2:23:33
Long COVID and post-vaccine syndromes: proposed mechanisms, dosing, and the FLCCC protocols
The guests pivot to long COVID, describing symptom clusters (fatigue, brain fog, cognitive issues) and proposing persistent inflammation triggered by lingering viral proteins. Dr. Kory reports clinical experiences using ivermectin (sometimes with steroids) and references FLCCC’s iRecover guidance, while noting limited formal trial data for long COVID specifically.
- •Long COVID symptoms: fatigue, fevers, pain, dizziness, brain fog, disability
- •Hypothesis: persistent inflammation driven by residual viral proteins (not active virus)
- •Ivermectin proposed roles: anti-inflammatory effects and possible interactions with spike
- •Clinical anecdotes vs trials: stronger claim of experience than RCT evidence for long COVID
- •FLCCC resources: iRecover protocol; discussion extends to post-vaccine symptom management
- 2:23:33 – 2:54:50
Censorship, public health messaging vs science, and the stakes of blocking debate
They argue that suppressing discussion prevents clinicians from learning, adapting, and saving lives—drawing parallels to earlier steroid debates where sharing frontline insights changed care. Bret distinguishes public health messaging (game theory, simplification) from scientific truth-seeking, warning that censorship tools inevitably get captured and misused.
- •Censorship expands from fringe claims (e.g., 5G) to legitimate scientific debate
- •Steroid story: early opposition, later validation, and harms from rigid protocol-following
- •Claim: suppression of ivermectin discussion has global life-and-death consequences
- •Public health may oversimplify; platforms treat it as scientific authority
- •Argument that open debate is the only mechanism to correct institutional errors
